MAP2K7 and hepatocellular carcinoma: Taken together, these findings suggested that DUSP4 deficiency induced Lenvatinib resistance through the activation of MAPK/ERK pathway and inhibition of MEK helped overcome Lenvatinib resistance in treating HCC.